"description","label","id","rationale","name","instanceType","uuid:ID"
"The main design for the study","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign","ccbd2c05-d57b-4af5-93c3-7e3b3f593782"
